Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Cabozantinib

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44336   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    70 result(s) found for: Cabozantinib. Displaying page 1 of 4.
    1  2  3  4  Next»
    EudraCT Number: 2018-001201-93 Sponsor Protocol Number: CABOPRE Start Date*: 2018-09-19
    Sponsor Name:Fundación ONCOSUR
    Full Title: Phase II study for the evaluation of neoadjuvant treatment with cabozantinib prior to cytoreductive nephrectomy in patients with locally advanced or metastatic renal cell carcinoma
    Medical condition: Locally Advanced or Metastatic Renal Cell Carcinoma
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10050513 Metastatic renal cell carcinoma PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Ongoing)
    Trial results: View results
    EudraCT Number: 2019-004728-39 Sponsor Protocol Number: AURORA Start Date*: 2020-07-31
    Sponsor Name:Frankfurter Institut für Klinische Krebsforschung IKF GmbH am Krankenhaus Nordwest
    Full Title: A Phase II, non-randomized, single arm, translational study of CAbozantinib for Patients with HepatocellUlaR CarcinOma (HCC) Refractory to first line TreAtment
    Medical condition: Locally advanced or metastatic and/or unresectable HCC
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2019-001142-18 Sponsor Protocol Number: 69HCL18_0977 Start Date*: 2019-04-17
    Sponsor Name:Hospices Civils de Lyon
    Full Title: Étude de tolérance au Cabozantinib dans le carcinome hépatocellulaire CLERANCE HCC (Cabozantinib toLERANCE study in HepatoCellular Carcinoma)
    Medical condition: HepatoCellular Carcinoma
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004864 10049010 Carcinoma hepatocellular LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed)
    Trial results: (No results available)
    EudraCT Number: 2017-004367-12 Sponsor Protocol Number: FCR173009 Start Date*: 2019-10-02
    Sponsor Name:Fundación CRIS de investigación para vencer el cáncer
    Full Title: A phase I-II study to evaluate the efficacy and safety of niraparib in combination with cabozantinib (XL184) in patients with advanced urothelial cancer after failure to first-line platinum-based c...
    Medical condition: Urinary tract or renal cell carcinoma
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10077840 Urothelial cancer of renal pelvis LLT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10038389 Renal cancer PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Ongoing)
    Trial results: View results
    EudraCT Number: 2013-003402-40 Sponsor Protocol Number: XL184-401 Start Date*: 2015-06-16
    Sponsor Name:Exelixis, Inc.
    Full Title: A Randomized, Double-blind Study To Evaluate the Efficacy and Safety of Cabozantinib (XL184) at 60 mg/Day Compared to 140 mg/Day in Progressive, Metastatic Medullary Thyroid Cancer Patients
    Medical condition: Progressive Metastatic Medullary Thyroid Cancer
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10027105 Medullary thyroid cancer PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Ongoing) SE (Completed) ES (Ongoing) FR (Completed) PL (Trial now transitioned) HU (Trial now transitioned) HR (Trial now transitioned) IT (Completed) RO (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2020-002075-35 Sponsor Protocol Number: MK-6482-011 Start Date*: 2020-12-21
    Sponsor Name:Merck Sharp & Dohme LLC
    Full Title: An Open-label, Randomized, Phase 3 Study of MK-6482 in Combination with Lenvatinib (MK-7902) vs Cabozantinib for Treatment in Participants with Advanced Renal Cell Carcinoma Who Have Progressed Aft...
    Medical condition: Renal cell carcinoma
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004864 10038409 Renal cell carcinoma NOS LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Trial now transitioned) FR (Trial now transitioned) BE (Trial now transitioned) AT (Trial now transitioned) FI (Trial now transitioned) IE (Trial now transitioned) IT (Trial now transitioned) PL (Trial now transitioned) GR (Trial now transitioned) CZ (Trial now transitioned) RO (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2020-000502-29 Sponsor Protocol Number: WO41994 Start Date*: 2020-09-01
    Sponsor Name:F. Hoffman-La Roche Ltd.
    Full Title: A PHASE III, MULTICENTER, RANDOMIZED, OPEN-LABEL STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ATEZOLIZUMAB GIVEN IN COMBINATION WITH CABOZANTINIB VERSUS CABOZANTINIB ALONE IN PATIENTS WITH INOPERAB...
    Medical condition: Renal cell carcinoma (RCC)
    Disease: Version SOC Term Classification Code Term Level
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10038395 Renal carcinoma LLT
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10038400 Renal carcinoma stage IV LLT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10050076 Metastatic renal carcinoma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Trial now transitioned) DK (Prematurely Ended) GB (GB - no longer in EU/EEA) GR (Completed) PL (Trial now transitioned) FR (Completed) IT (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2018-003354-24 Sponsor Protocol Number: XL184–312 Start Date*: Information not available in EudraCT
    Sponsor Name:Exelixis, Inc.
    Full Title: A Randomized, Controlled Phase 3 Study of Cabozantinib (XL184) in Combination with Atezolizumab versus Sorafenib in Subjects with Advanced Hepatocellular Carcinoma Who Have Not Received Previous...
    Medical condition: Hepatocellular carcinoma
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10029104 Neoplasms benign, malignant and unspecified (incl cysts and polyps) SOC
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: CZ (Completed) HU (Trial now transitioned) NL (Completed) ES (Ongoing) BE (Trial now transitioned) DE (Completed) AT (Completed) PL (Completed) FR (Trial now transitioned) GB (GB - no longer in EU/EEA) IT (Completed) RO (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2021-005549-34 Sponsor Protocol Number: 2021/653 Start Date*: 2022-02-10
    Sponsor Name:CHU Besançon
    Full Title: Cabo-POLARIS. Etude de phase 2 prospective multicentrique en ouvert pour évaluer la durée de traitement par cabozantinib chez les patients atteints de carcinome rénal métastatique ou localement ava...
    Medical condition: carcinome à cellules rénales avancé ou métastatique.
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed)
    Trial results: (No results available)
    EudraCT Number: 2014-000501-13 Sponsor Protocol Number: 1317-STBSG Start Date*: 2017-02-10
    Sponsor Name:European Organisation for Research and Treatment of Cancer (EORTC)
    Full Title: Phase II study of cabozantinib in patients with metastatic gastrointestinal stromal tumor (GIST) who progressed during neoadjuvant, adjuvant or palliative therapy with imatinib and sunitinib
    Medical condition: metastatic gastrointestinal stromal tumor (GIST)
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000016768 10062427 Gastrointestinal stromal tumor LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed) DE (Completed) HU (Completed) GB (GB - no longer in EU/EEA)
    Trial results: View results
    EudraCT Number: 2019-001639-30 Sponsor Protocol Number: CABOMAYOR Start Date*: 2019-10-15
    Sponsor Name:Spanish Oncology Genitourinary Group - SOGUG
    Full Title: Pilot study of cabozantinib efficacy, safety and tolerability in metastatic renal carcinoma in aged fragile patients: CABOMAYOR study
    Medical condition: Metastatic renal cell carcinoma
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004864 10050076 Metastatic renal carcinoma LLT
    Population Age: Elderly Gender: Male, Female
    Trial protocol: ES (Ongoing)
    Trial results: View results
    EudraCT Number: 2022-000391-19 Sponsor Protocol Number: CAT_AOSPTR001 Start Date*: 2022-04-19
    Sponsor Name:AZIENDA OSPEDALIERA "S. MARIA"
    Full Title: A Single Arm Phase II Study of CAbozantinib in relapsing IDH-1wt, MET amplified Glioblastoma: (“CAT” Study)
    Medical condition: recurrent or progressive glioblastoma with c-MET hyperexpression
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10018336 Glioblastoma PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2019-002184-97 Sponsor Protocol Number: CABOCOL-01 Start Date*: 2019-10-10
    Sponsor Name:Centre François Baclesse
    Full Title: A phase II study assessing safety and efficacy of Cabozantinib for advanced or metastatic cervical carcinoma after platinum treatment failure
    Medical condition: Recurrent unresectable or metastatic cervix carcinoma
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10008344 Cervix carcinoma recurrent PT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: FR (Completed)
    Trial results: (No results available)
    EudraCT Number: 2020-000775-20 Sponsor Protocol Number: CaboRISE Start Date*: 2020-08-31
    Sponsor Name:Frankfurter Institut für Klinische Krebsforschung IKF GmbH am Krankenhaus Nordwest
    Full Title: A phase II study evaluating reduced starting dose and dose escalation of Cabozantinib as second-line therapy for advanced HCC in patients with preserved liver function
    Medical condition: Advanced stage hepatocellular carcinoma (HCC) patients with preserved liver function in second line therapy
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2018-000363-91 Sponsor Protocol Number: CX-839-008 Start Date*: 2018-08-10
    Sponsor Name:Calithera Biosciences Inc
    Full Title: A Randomized, Double-Blind, Placebo-Controlled Phase 2 Clinical Trial Comparing CB-839 in Combination with Cabozantinib (CB-Cabo) vs. Placebo with Cabozantinib (Pbo-Cabo) in Patients with Advanced ...
    Medical condition: Advanced or metastatic clear-cell renal cell carcinoma
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA) ES (Prematurely Ended) DE (Ongoing) IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2018-000682-36 Sponsor Protocol Number: NL65109.091.18 Start Date*: 2018-07-05
    Sponsor Name:Radboud university medical center
    Full Title: The efficacy of cabozantinib in advanced salivary gland cancer patients, a phase II clinical trial
    Medical condition: Salivary gland cancer
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2017-003103-22 Sponsor Protocol Number: BONSAI Start Date*: 2017-11-28
    Sponsor Name:FONDAZIONE IRCCS "ISTITUTO NAZIONALE DEI TUMORI"
    Full Title: Advanced or Metastatic Collecting ducts renal cell carcinoma
    Medical condition: Collecting Duct Renal Cell Carcinoma
    Disease: Version SOC Term Classification Code Term Level
    21.0 100000004864 10073252 Carcinoma of the collecting ducts of Bellini LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2018-000582-36 Sponsor Protocol Number: BREAKPOINT Start Date*: 2018-05-17
    Sponsor Name:FONDAZIONE IRCCS "ISTITUTO NAZIONALE DEI TUMORI"
    Full Title: A phase 2 open label study of caBozantinib in patients with advanced or unresectable Renal cEll cArcinoma pretreated with one immunochecKPOint INhibiTor (anti PD1/PDL1)
    Medical condition: Patients with metastatic clear cell renal cell carcinoma pretreated with immunocheckpoints inhibitors
    Disease: Version SOC Term Classification Code Term Level
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10073251 Clear cell renal cell carcinoma PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2020-002541-41 Sponsor Protocol Number: 02679 Start Date*: 2021-04-23
    Sponsor Name:Universitätsmedizin Göttingen
    Full Title: A phase II trial of Cabozantinib in patients with advanced, low proliferative NEN G3.
    Medical condition: We will include patients with NET G3 and upto four prior antitumoral treatment lines and NEC Ki67 low after failure of standard treatment with conventional chemotherapy.
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Trial now transitioned) AT (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2013-000762-11 Sponsor Protocol Number: 62113-55115 Start Date*: 2014-10-20
    Sponsor Name:European Organisation for Research and Treatment of Cancer (EORTC)
    Full Title: A randomized double-blind phase II study evaluating the role of maintenance therapy with cabozantinib in High Grade Undifferentiated Uterine Sarcoma (HGUS) after stabilization or response to doxoru...
    Medical condition: High Grade Undifferentiated Uterine Sarcoma (HGUS)
    Disease: Version SOC Term Classification Code Term Level
    18.0 100000004864 10046821 Uterine sarcoma NOS LLT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: BE (Completed) IT (Completed) ES (Completed) DE (Completed) GB (GB - no longer in EU/EEA) NL (Completed)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  4  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Sat May 17 13:58:39 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA